From immune mechanisms to more precise sarcoidosis diagnosis

From immune mechanisms to more precise sarcoidosis diagnosis

Publication date on this website: 7 October 2026.
Date of the original paper: 1 March 2026.

Introduction
Sarcoidosis is a multisystem granulomatous disease whose causes and course are still being investigated. A new review of immune mechanisms examines how the interaction between the innate and adaptive immune systems may shape granuloma formation, clinical phenotypes, and future diagnostic approaches.

Extended summary
The authors describe sarcoidosis as likely arising from a combination of genetic predisposition, environmental exposures, and an improperly regulated immune response. Activation of innate immune cells may trigger granuloma formation, while T lymphocytes and other adaptive immune cells maintain or modulate the inflammatory response. Different organs and patients may show different patterns of immune activity, which is why the disease does not present clinically in the same way in everyone.

The review also discusses biomarkers and the possibility of more precise diagnosis. The idea is to combine clinical data, radiological findings, laboratory markers, and molecular or immune profiles. Such approaches may help distinguish active inflammation from permanent scarring, but most are not yet ready for independent routine use without confirmation in larger studies.

What is new
The paper connects current knowledge about immune pathways with the need to phenotype patients. Future research may enable the selection of biomarkers and therapeutic targets according to each patient’s disease pattern, but this is a research direction, not an established clinical method.

Why it matters to people with sarcoidosis and clinicians
For people with sarcoidosis, the text explains why the disease can affect different organs and why a single laboratory test is usually not sufficient to diagnose the disease or assess its activity. For clinicians, the review may help in understanding the development of new biomarkers and targeted therapies. At present, decisions are still based on the overall clinical picture, rather than on a single immune marker.

Limitations of the evidence
This is a review article covering heterogeneous experimental and clinical evidence. Immune findings may depend on the sample, laboratory method, affected organ, and stage of disease. Many proposed biomarkers have not yet been sufficiently validated for routine diagnosis or monitoring.

Conclusion
A better understanding of immune mechanisms may contribute to more precise diagnosis and individualized treatment of sarcoidosis. For now, the most important approach is to interpret research findings in the context of clinical examination, imaging, and standard laboratory tests.

Source and bibliographic details
Immunopathogenesis and emerging biomarkers in sarcoidosis. Autoimmunity Reviews. 2026;25(3):103993. DOI: 10.1016/j.autrev.2026.103993.
Source: https://doi.org/10.1016/j.autrev.2026.103993

Medical note
This text is for informational purposes and does not replace a medical examination, diagnosis, or individualized medical advice. Do not interpret test results independently, change treatment, or draw conclusions about disease activity based on a single biomarker. Discuss the results and their significance with your doctor.